Related Experiment Video
Updated: Jun 28, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
AKR1C3-negative high-risk metastatic castration-sensitive prostate cancer has long-term response to first-line
Tsuyoshi Yoshizawa1, Yoko Nakanishi2, Daisuke Obinata1
1Department of Urology, Nihon University School of Medicine, Japan.
Abstract:
We experienced four cases of high-risk metastatic castration-sensitive prostate cancer (mCSPC) in which first-line treatment with abiraterone showed a sustained long-term response of over 5 years. We conducted immunohistochemical staining of aldo-keto reductase family 1 member C3 (AKR1C3) expression, which associate with poor prognosis of metastatic castration-resistant prostate cancer (mCRPC), and all prostate cancer tissue from four cases showed negative. These results suggested that AKR1C3-negative high-risk mCSPC cases may respond well to first-line treatment with abiraterone. This is the first report describing association of high-risk mCSPC and negative AKR1C3.
Insights
High-risk metastatic castration-sensitive prostate cancer (mCSPC) patients with negative AKR1C3 expression showed sustained long-term response to abiraterone. This suggests a potential biomarker for predicting treatment efficacy in mCSPC.
Area of Science:
- Oncology
- Urology
- Medical Biochemistry
Background:
- Metastatic castration-sensitive prostate cancer (mCSPC) requires effective first-line treatments.
- Abiraterone acetate is a standard treatment for advanced prostate cancer.
- Prognostic markers for treatment response in mCSPC are crucial.
Observation:
- Four cases of high-risk mCSPC were treated with first-line abiraterone.
- Tumor tissue analysis revealed negative expression of aldo-keto reductase family 1 member C3 (AKR1C3).
- All patients demonstrated sustained responses exceeding 5 years.
Findings:
- Negative AKR1C3 expression in high-risk mCSPC correlates with long-term response to abiraterone.
- AKR1C3 is typically associated with poor prognosis in metastatic castration-resistant prostate cancer (mCRPC).
- This study is the first to report the association between high-risk mCSPC, negative AKR1C3, and abiraterone response.
Implications:
- Negative AKR1C3 may serve as a predictive biomarker for abiraterone efficacy in high-risk mCSPC.
- This finding could guide personalized treatment strategies for prostate cancer patients.
- Further research is warranted to validate AKR1C3 as a biomarker in larger mCSPC cohorts.
